Breast cancer-specific survival by molecular subtype in different age groups of women in Scotland

Background: Age and molecular subtypes are important prognostic factors in breast cancer (BC). Here, we explore how age and molecular subtypes influence BC survival in Scotland.
Methods: We analysed data from 71,784 women diagnosed with invasive BC in Scotland between 1997 and 2016, with follow-up until 31st December 2018 (median follow-up time=5.5 years). Cox models estimated Hazard Ratios (HR) for BC-specific death by age group (with women of screening age, 50-69 years old, as the reference) within each molecu-lar subtype, adjusting for prognostic factors. The cumulative incidence function was plotted to account for competing risks.
Results: During the study period, 37% of women died, with 53% of deaths attributed to BC. Women aged 70+ years had increased BC-specific death compared to women aged 50 to 69 years with the same subtype. HRs (95% CI) were 1.49 (1.23 - 1.80) for luminal A, 1.39 (1.14 to 1.69) for luminal B tumours and 1.49 (1.15 to 1.94) for triple negative breast cancer (TNBC). Women aged <50 years had lower risk of BC death in luminal A subtype only, with HR of 0.66 (0.51 - 0.86) compared to women aged 50 to 69 years. Competing risks analysis showed higher cumulative incidence of death from non-BC causes, particularly for women aged 70+ years with hormone positive subtypes. Stage, treatment, and molecular subtype were the strongest prognostic factors for BC-specific mortality across all ages.
Conclusions: Age influences BC-specific mortality particularly within luminal subtypes. In contrast, other tumour characteristics and treatment are key prognostic factors for non-luminal subtypes. Future studies should investigate other markers of BC mortality particu-larly among over 70-year-olds, who account for 60% of BC deaths in the UK.